Ioversol

CHEMBL1200614 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
807.1 g/mol
LogP
-3.0
Phase
4

This non-ionic, low-osmolality iodinated contrast agent is used for coronary angiography, CT scans, urography, and other diagnostic imaging. Its favorable safety profile makes it suitable for a wide range of patients including those with mild to moderate renal impairment. Standard precautions for iodinated contrast including allergy screening and post-procedure hydration apply.

Molekularmasse

807,1000 g/mol

LogP

-3,00

TPSA

200,00 Ų

Lipinski-Regel der Fünf

Nicht bestanden

Therapeutische Bereiche

Wirkmechanismus

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C(NCC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(N(CCO)C(=O)CO)c1I

InChI

InChI=1S/C18H24I3N3O9/c19-13-11(17(32)22-3-8(29)5-26)14(20)16(24(1-2-25)10(31)7-28)15(21)12(13)18(33)23-4-9(30)6-27/h8-9,25-30H,1-7H2,(H,22,32)(H,23,33)

Molecular Formula

C18H24I3N3O9

HBD / HBA

8 / 9

Rotierbare Bindungen

12

Schwere Atome

33

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

This non-ionic, low-osmolality iodinated contrast agent is used for coronary angiography, CT scans, urography, and other diagnostic imaging. Its favorable safety profile makes it suitable for a wide range of patients including those with mild to moderate renal impairment. Standard precautions for iodinated contrast including allergy screening and post-procedure hydration apply.

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Yes, Ioversol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200614. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3741. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.